- Home
- EAF vs KROS Comparison
EAF vs KROS Comparison
Compare EAF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | KROS |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 206.0M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAF | KROS |
|---|---|---|
| Price | $6.85 | $10.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $11.75 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 275.8K | 197.0K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $243,864,000.00 |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $9.69 |
| 52 Week High | $20.32 | $22.55 |
Technical Indicators
Market Signals| Indicator | EAF | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 53.60 |
| Support Level | $6.16 | $10.57 |
| Resistance Level | $8.21 | $11.51 |
| Average True Range (ATR) | 0.43 | 0.56 |
| MACD | -0.11 | 0.07 |
| Stochastic Oscillator | 15.88 | 70.40 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.